Rhumbline Advisers Makes New Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Rhumbline Advisers purchased a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,993 shares of the company’s stock, valued at approximately $102,000. Rhumbline Advisers owned about 0.10% of Cardiff Oncology at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CRDF. Callan Capital LLC grew its holdings in Cardiff Oncology by 37.2% in the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after purchasing an additional 11,600 shares during the period. Bank of New York Mellon Corp acquired a new position in Cardiff Oncology during the 2nd quarter worth $256,000. Blair William & Co. IL grew its position in shares of Cardiff Oncology by 32.4% in the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock worth $919,000 after acquiring an additional 42,180 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Cardiff Oncology by 380.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after purchasing an additional 962,940 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock valued at $10,260,000 after purchasing an additional 9,468 shares during the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Stock Down 3.6 %

Shares of Cardiff Oncology stock opened at $2.67 on Tuesday. The business has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $3.22. Cardiff Oncology, Inc. has a fifty-two week low of $0.94 and a fifty-two week high of $6.42. The firm has a market cap of $124.29 million, a price-to-earnings ratio of -2.97 and a beta of 1.95.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same period in the prior year, the company earned ($0.25) earnings per share. Analysts anticipate that Cardiff Oncology, Inc. will post -1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Craig Hallum began coverage on Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 price objective for the company.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.